PDCD1 and colorectal carcinoma: Pembrolizumab and nivolumab are efficient for treatment of metastatic CRC with deficient mismatch repair (MMR) or high microsatellite instability (MSI‐H), for which accelerated FDA approval have been granted for two promising programmed cell death 1 (PD1)‐blocking antibodies4 in CRC.